cUTI

New antibiotic for MRSA on the horizon
New antibiotic for MRSA on the horizonAs the healthcare profession continues to face challenges with antibiotic resistance, drugmakers are developing novel antibiotics that will be effective against some of the worst infections. One drugmaker submitted New Drug Applications (NDAs) for approval of IV and oral delafloxacin (Baxdela) to FDA.
FDA approves ceftazidime-avibactam to treat two complicated infectionsThe combination product is indicated to treat either complicated intra-abdominal infections, where it is used in combination with metronidazole, or complicated urinary tract infections in patients with few or no other treatment options.